📊 GH Key Takeaways
Is Guardant Health, Inc. (GH) a Good Investment?
Guardant Health faces severe financial distress with negative stockholders' equity of -$99.3M, indicating liabilities exceed assets by this amount. The company is burning cash at an alarming rate with negative operating cash flow of -$184.8M and negative free cash flow of -$233.1M, while generating negative net income of -$416.3M on flat revenue growth. Without significant operational improvements or capital injections, the company's financial viability is at critical risk despite maintaining adequate short-term liquidity.
Guardant Health shows weak fundamentals: revenue is flat while operating and net losses remain extremely large, with negative operating margin of -44.5% and net margin of -42.4%. Financial health is pressured by negative equity, $1.50B of long-term debt, and deeply negative free cash flow, although the cash balance and strong current ratio provide some near-term liquidity support.
Why Buy Guardant Health, Inc. Stock? GH Key Strengths
- Strong current ratio of 4.84x provides adequate short-term liquidity buffer
- Substantial cash reserves of $378.2M offer runway to fund operations in near term
- Position in medical diagnostics sector addresses important healthcare market needs
- Strong near-term liquidity with 4.84x current ratio and $378.20M in cash
- Meaningful revenue base of $982.02M provides operating scale to build on
- Diluted EPS improved modestly year over year, suggesting some incremental cost progress
GH Stock Risks: Guardant Health, Inc. Investment Risks
- Negative stockholders' equity indicates technical insolvency with liabilities exceeding assets
- Severe cash burn rate of -$233.1M in free cash flow is unsustainable; cash reserves deplete in ~1.6 years at current rate
- Persistent unprofitability with -44.5% operating margin and -42.4% net margin; zero revenue growth indicates market saturation or execution failure
- Negative interest coverage of -112.2x indicates inability to service debt obligations from operations
- Long-term debt of $1.5B represents 79% of total assets, creating refinancing risk if liquidity deteriorates
- Profitability remains very weak, with large operating and net losses despite nearly $1B in revenue
- Negative stockholders equity indicates a stressed balance sheet and limits financial flexibility
- Negative operating cash flow and free cash flow increase reliance on external funding over time
Key Metrics to Watch
- Operating cash flow trend - must turn positive to avoid insolvency
- Gross margin - need visibility into unit economics and pricing power
- Revenue growth acceleration - flat growth unsustainable given burn rate
- Path to EBITDA positive - critical to assess operational viability
- Debt covenant compliance - risk of default if leverage ratios breached
- Revenue growth reacceleration versus continued flat sales
- Operating cash flow burn and progress toward sustained margin improvement
Guardant Health, Inc. (GH) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 4.84x current ratio provides a solid financial cushion.
GH Profit Margin, ROE & Profitability Analysis
GH vs Healthcare Sector: How Guardant Health, Inc. Compares
How Guardant Health, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Guardant Health, Inc. Stock Overvalued? GH Valuation Analysis 2026
Based on fundamental analysis, Guardant Health, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Guardant Health, Inc. Balance Sheet: GH Debt, Cash & Liquidity
GH Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Guardant Health, Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-4.28 indicates the company is currently unprofitable.
GH Revenue Growth, EPS Growth & YoY Performance
GH Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $191.5M | -$92.7M | $-0.74 |
| Q2 2025 | $177.2M | -$99.9M | $-0.80 |
| Q1 2025 | $168.5M | -$95.2M | $-0.77 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Guardant Health, Inc. Dividends, Buybacks & Capital Allocation
GH SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Guardant Health, Inc. (CIK: 0001576280)
📋 Recent SEC Filings
| Date | Form | Document | Action |
|---|---|---|---|
| Apr 7, 2026 | 4 | xslF345X06/wk-form4_1775598001.xml | View → |
| Apr 2, 2026 | 4 | xslF345X06/wk-form4_1775165051.xml | View → |
| Apr 2, 2026 | 4 | xslF345X06/wk-form4_1775165016.xml | View → |
| Apr 2, 2026 | 4 | xslF345X06/wk-form4_1775164975.xml | View → |
| Apr 2, 2026 | 4 | xslF345X06/wk-form4_1775164935.xml | View → |
❓ Frequently Asked Questions about GH
What is the AI rating for GH?
Guardant Health, Inc. (GH) has a Combined AI Rating of STRONG SELL from Claude (STRONG SELL) and ChatGPT (STRONG SELL) with 92% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are GH's key strengths?
Claude: Strong current ratio of 4.84x provides adequate short-term liquidity buffer. Substantial cash reserves of $378.2M offer runway to fund operations in near term. ChatGPT: Strong near-term liquidity with 4.84x current ratio and $378.20M in cash. Meaningful revenue base of $982.02M provides operating scale to build on.
What are the risks of investing in GH?
Claude: Negative stockholders' equity indicates technical insolvency with liabilities exceeding assets. Severe cash burn rate of -$233.1M in free cash flow is unsustainable; cash reserves deplete in ~1.6 years at current rate. ChatGPT: Profitability remains very weak, with large operating and net losses despite nearly $1B in revenue. Negative stockholders equity indicates a stressed balance sheet and limits financial flexibility.
What is GH's revenue and growth?
Guardant Health, Inc. reported revenue of $982.0M.
Does GH pay dividends?
Guardant Health, Inc. does not currently pay dividends.
Where can I find GH SEC filings?
Official SEC filings for Guardant Health, Inc. (CIK: 0001576280) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is GH's EPS?
Guardant Health, Inc. has a diluted EPS of $-3.32.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is GH a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Guardant Health, Inc. has a STRONG SELL rating with 92% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is GH stock overvalued or undervalued?
Valuation metrics for GH: ROE of N/A (sector avg: 15%), net margin of -42.4% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy GH stock in 2026?
Our dual AI analysis gives Guardant Health, Inc. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is GH's free cash flow?
Guardant Health, Inc.'s operating cash flow is $-184.8M, with capital expenditures of $48.3M. FCF margin is -23.7%.
How does GH compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -42.4% (avg: 12%), ROE N/A (avg: 15%), current ratio 4.84 (avg: 2).